An Introduction to Thyroid Disorders
Thyroid disorders encompass primary thyroid disease (hypothyroidism, thyrotoxicosis, thyroid enlargement), thyroid cancer and thyroid disease in pregnancy. Hypothyroidism is a highly prevalent global health problem. It can be successfully managed by lifelong treatment with levothyroxine, but challenges include underdiagnosis, optimal treatment of subclinical hypothyroidism, and the use of levothyroxine monotherapy versus combination with triiodothyronine. Thyroid cancer advances include therapies targeting the MAPK and PI3K/AKT/mTOR pathways, or VEGF, and have resulted in significant clinical benefits. Immunotherapies also appear promising. However, improved options are needed for patients with radioiodine-refractory differentiated thyroid cancer and undifferentiated cancers.
Browse our gallery of video highlights and short articles from the conference hub, providing the latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Thyroid Disorders Content
Julie Ann Sosa, MD, MA, FACS: American Thyroid Association (ATA) centennial celebration
We caught up with the American Thyroid Association (ATA) president Prof. Julie Ann Sosa, MD, MA, FACS (University of California, San Francisco, CA, USA) ahead of this year’s virtual meeting to highlight their ATA Centennial Celebration at their upcoming conference taking place in Washington, DC in 2023. The 2023 American Thyroid Association Annual Meetings Centennial […]
Thyrotoxic Cardiomyopathy: State of the Art
touchREVIEWS in Endocrinology. 2023;19(1):78-84
Thyrotoxicosis refers to the signs and symptoms derived from excess circulating thyroid hormones in the body,1 which must be differentiated from hyperthyroidism, in which there is an increase in the synthesis and secretion of hormones by the thyroid gland.2 Approximately 1% of patients with thyrotoxicosis develop thyrotoxic cardiomyopathy (TCM), which is a rare but potentially lethal form […]
Coexistence of Thyrolipomatosis and Tongue Squamous Cell Carcinoma: A Case Report
touchREVIEWS in Endocrinology. 2023;19(1):103-7
Thyrolipomatosis is a rare condition defined as a diffuse non-neoplastic infiltration of fatty tissue in the thyroid gland.1 Although fatty infiltration is common in other glands (e.g. salivary glands, parathyroids, thymus and pancreas), it is rare in the thyroid gland.2 If present, it is most frequently nodular (i.e. thyrolipoma) rather than diffuse (i.e. thyrolipomatosis).3 Thus, since the first […]
Glenn Braunstein: Research highlights from 2022 in thyroid disorders
There has also been high interest in the treatment of hypothyroidism in older adults, the treatment of thyroid eye disease and the increase of radiofrequency ablation for thyroid nodules to reduce their size by 50% to 97%. We were delighted to speak with our editorial board member Prof. Glenn Braunstein (Cedars-Sinai Medical Center, Los Angeles, […]
Kristien Boelaert, ATA 2022: The EGRET study: Long term mortality and cardiometabolic effects of hyperthyroidism treatment
Current evidence indicates cardio‐metabolic effects from antithyroid drugs and other definitive treatment options for hyperthyroidism. The EGRET study aimed to assess the differences in mortality and cardiometabolic outcomes depending on the method of treatment in order to better inform patient‐clinician decision‐making. In this touchENDOCRINOLOGY interview, Prof. Kristien Boelaert (University of Birmingham, Birmingham, United Kingdom) discusses […]
Kristien Boelaert, ATA 2022: Challenges of the long term treatment of hyperthyroidism
Hyperthyroidism, also called overactive thyroid, occurs when your thyroid gland overproduces thyroid hormones. In this touchENDOCRINOLOGY interview, Prof. Kristien Boelaert (University of Birmingham, Birmingham, United Kingdom) discusses the challenges faced in the long term treatment of hyperthyroidism. The abstract entitled: ‘LONG‐TERM MORTALITY AND CARDIOMETABOLIC EFFECTS OF TREATMENT FOR HYPERTHYROIDISM: EGRET STUDY‘ was presented at the American […]
Thyroid Function During and After COVID-19 Infection: A Review
touchREVIEWS in Endocrinology. 2022;18(1):58–62 DOI: https://doi.org/10.17925/EE.2022.18.1.58
On 31 December 2019, the World Health Organization (WHO) was notified of several cases of pneumonia of unknown aetiology in Wuhan, China. After a relatively short period, officials confirmed the first case of coronavirus disease 2019 (COVID-19) reported outside of China, in Thailand, on 13 January 2020.1 From the start of the pandemic to 11 November […]
Personalized treatment of RET-altered thyroid cancers: What is the value of biomarker testing and targeted therapies?
Leading experts explain the value of biomarker testing and targeted therapies for the personalized treatment of RET-altered thyroid cancers
- Distinguish between different types of thyroid cancers and describe therapies that are appropriate for their management
- Plan a personalized approach to treatment of RET-altered thyroid cancers, including use of biomarker testing and novel targeted therapies
- Evaluate the clinical trial data for novel targeted therapies for RET-altered thyroid cancers and apply it to clinical practice
Presentation of Pseudohypoparathyroidism Type 1b with Albright Hereditary Osteodystrophy and Laryngospasm: Case Report
US Endocrinology. 2021;17(1):Online ahead of journal publication
The clinical presentation of hypocalcemia varies based on the degree and chronicity of the derangement. Although many patients remain asymptomatic, mild symptoms of hypocalcemia include circumoral and extremity paresthesia, Chvostek’s sign and Trousseau’s sign; more severe derangements can present with cardiac arrythmias and seizures.1–3 Chronic hypocalcemia may present with cataracts and basal ganglia calcifications.2,3 Due […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!